Icatibant Gp-Pharm

Icatibant, the active ingredient in Icatibant Gp-Pharm, is a bradykinin B2 receptor antagonist presented as a sterile solution for subcutaneous injection. It is indicated for the treatment of acute hereditary angioedema attacks in patients with C1‑inhibitor deficiency, providing rapid symptom relief by blocking bradykinin‑mediated vascular effects.

GNH USA supplies Icatibant Gp-Pharm as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide with adherence to quality standards and regulatory requirements, and providing reliable logistics support for timely distribution.

Icatibant is used to manage hereditary angioedema, a condition driven by excessive bradykinin activity. - Acute HAE type I attacks: rapid reduction of swelling and pain during episodes. - Acute HAE type II attacks: rapid reduction of swelling and pain during episodes. - Hereditary angioedema with C1‑inhibitor deficiency: alleviates edema during acute attacks.

Icatibant may be associated with several adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness: localized erythema around the injection area. - Swelling: transient edema at the site of administration. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis requiring medical attention. - Airway edema: rare worsening of angioedema affecting the throat. - Severe hypotension: uncommon drop in blood pressure after injection.

Before using Icatibant, several precautionary measures should be considered to ensure safe administration. - Assess patient history: confirm diagnosis of hereditary angioedema and C1‑inhibitor deficiency. - Monitor for hypersensitivity: observe for signs of allergic reaction after each dose. - Avoid use in patients with known B2 receptor hypersensitivity. - Consider renal or hepatic impairment: adjust monitoring as needed. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that influence bradykinin pathways or fluid balance.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and exacerbate angioedema. - Other bradykinin B2 antagonists: concurrent use may lead to additive effects.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may influence HAE severity; monitor clinical response. - Diuretics: may affect fluid balance; observe for edema changes. - Immunosuppressants: no direct interaction but monitor infection risk.